ethyl 2-ethoxycarbonyl-1-cyclohexylidenecyanoacetate | 56955-19-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: ethyl 2-ethoxycarbonyl-1-cyclohexylidenecyanoacetate
• 英文别名: seqcis-2-Ethoxycarbonyl-cyclohexyliden-cyanessigsaeure-ethylester；ethyl (2Z)-2-(1-cyano-2-ethoxy-2-oxoethylidene)cyclohexane-1-carboxylate
• CAS: 56955-19-2
• 化学式: C₁₄H₁₉NO₄
• 分子量: 265.309
• InChiKey: RRVJRAMJENYMRC-BENRWUELSA-N

物化性质

• 沸点：
  160-170 °C(Press: 1 Torr)
• 密度：
  1.141±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  76.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 2-ethoxycarbonyl-1-cyclohexylidenecyanoacetate 在 吗啉 、 sulfur 作用下， 以 乙醇 为溶剂， 反应 5.0h， 以52%的产率得到diethyl (R,S)-2-amino-4,5,6,7-tetrahydrobenzothiophene-3,4-dicarboxylate
  参考文献：
  名称：

  Naumann; Bohm; Fuloep, Pharmazie, 1996, vol. 51, # 1, p. 4 - 6

  摘要：

  DOI：

文献信息

• SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF
  申请人：JAGTAP Prakash

  公开号：US20100261706A1

  公开（公告）日：2010-10-14

  Provided herein are tetracyclic 1H-indeno[1,2-b]pyridine-2(5H)-one analogs and derivatives, compositions comprising an effective amount of a tetracyclic 1H-indeno[1,2-b]pyridine-2(5H)-one analog and/or derivative and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, a reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, an ocular or opthalmologic disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, contrast induced nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of a tetracyclic 1H-indeno[1,2-b]pyridine-2(5H)-one analog or derivative.

  本文提供四环1H-吲哚[1,2-b]吡啶-2(5H)-酮类似物和衍生物，包括含有效量四环1H-吲哚[1,2-b]吡啶-2(5H)-酮类似物和/或衍生物的组合物以及治疗或预防炎症性疾病、再灌注损伤、糖尿病、糖尿病并发症、器官移植引起的再氧化损伤、缺血症、神经退行性疾病、肾功能衰竭、血管疾病、心血管疾病、眼部或眼科疾病、癌症、早产并发症、心肌病、视网膜病、肾病、造影剂诱导性肾病、神经病和勃起功能障碍或尿失禁的方法，包括向需要的受体施用有效量的四环1H-吲哚[1,2-b]吡啶-2(5H)-酮类似物或衍生物。
• Heterotricyclic metalloprotease inhibitors
  申请人：Gege Christian

  公开号：US20080207607A1

  公开（公告）日：2008-08-28

  The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
• Heterotricyclic Metalloprotease Inhibitors
  申请人：Gege Christian

  公开号：US20100087420A1

  公开（公告）日：2010-04-08

  The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
• US7749996B2
  申请人：——

  公开号：US7749996B2

  公开（公告）日：2010-07-06
• [EN] SUBSTITUTED TETRACYCLIC 1H-INDENO (1,2-B) PYRIDINE-2 (5H)-ONE ANALOGS THEREOF AND USES THEREOF<br/>[FR] ANALOGUES TÉTRACYCLIQUES SUBSTITUÉS DE 1H-INDÉNO(1,2-B)PYRIDINE-2(5H)-ONE ET LEURS UTILISATIONS
  申请人：INOTEK PHARMACEUTICALS CORP

  公开号：WO2010077663A2

  公开（公告）日：2010-07-08

  Provided herein are tetracyclic 1H-indeno[1,2-b]pyridine-2(5H)-one analogs and derivatives, compositions comprising an effective amount of a tetracyclic 1H- indeno[1,2-b]pyridine-2(5H)-one analog and/or derivative and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, a reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, an ocular or ophthalmologic disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, contrast induced nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of a tetracyclic 1H- indeno[1,2-b]pyridine-2(5H)-one analog or derivative.